Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 9041-08-1
Drug Levels and Effects
Summary of Use during Lactation
Because of the low levels of dalteparin in breastmilk and its large molecular weight of 2000 to 9000 daltons, amounts ingested by the infant are small and it would not be expected to be absorbed from breastmilk by the infant. No special precautions are required.[1]
Drug Levels
Maternal Levels. In two women receiving subcutaneous dalteparin 5000 IU and 10,000 IU daily, respectively, dalteparin was undetectable in breastmilk.[2]
Anti-Xa activity (a measurement of anticoagulant activity) was measured in the milk of 15 patients before and 3 to 4 hours after 4 to 8 days at a daily dosage of 2500 IU subcutaneously. Anti-Xa activity in milk ranged from less than 5 to 37 IU/L which was 2.5 to 22.4% of the simultaneous maternal plasma anti-Xa activity.[3]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Although not clearly stated, it appears that 15 neonates were breastfed during maternal dalteparin use in one study with no adverse effects reported.[3]
In another report, one mother breastfed her infant for 20 days starting at 7 weeks of age while taking subcutaneous dalteparin 5000 IU subcutaneously twice daily with no adverse effects to her infant.[4]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv 2018;2:3317-59. [PMC free article: PMC6258928] [PubMed: 30482767]
- 2.
- Harenberg J, Leber G, Zimmermann R, et al. [Prevention of thromboembolism with low-molecular weight heparin in pregnancy]. Geburtshilfe Frauenheilkd 1987;47:15-8. [PubMed: 3569823]
- 3.
- Richter C, Sitzmann J, Lang P, et al. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001;52:708-10. [PMC free article: PMC2014571] [PubMed: 11736885]
- 4.
- Lindhoff-Last E, Willeke A, Thalhammer C, et al. Hirudin treatment in a breastfeeding woman. Lancet 2000;355:467-8. [PubMed: 10841132]
Substance Identification
Substance Name
Dalteparin
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Enoxaparin.[Drugs and Lactation Database (...]Review Enoxaparin.. Drugs and Lactation Database (LactMed®). 2006
- Review Melatonin.[Drugs and Lactation Database (...]Review Melatonin.. Drugs and Lactation Database (LactMed®). 2006
- A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.[Health Technol Assess. 2001]A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Health Technol Assess. 2001; 5(32):1-195.
- Water precautions for prevention of infection in children with ventilation tubes (grommets).[Cochrane Database Syst Rev. 2016]Water precautions for prevention of infection in children with ventilation tubes (grommets).Moualed D, Masterson L, Kumar S, Donnelly N. Cochrane Database Syst Rev. 2016 Jan 27; 2016(1):CD010375. Epub 2016 Jan 27.
- Review The Black Book of Psychotropic Dosing and Monitoring.[Psychopharmacol Bull. 2024]Review The Black Book of Psychotropic Dosing and Monitoring.DeBattista C, Schatzberg AF. Psychopharmacol Bull. 2024 Jul 8; 54(3):8-59.
- Dalteparin - Drugs and Lactation Database (LactMed®)Dalteparin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...